Logo Image
NEWS
Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted Pulse
CONFERENCES
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
MEDIA
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPractice PlaybookShortsVideo Series
PUBLICATIONS
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
More
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
  • NEWS
  • CONFERENCES
  • MEDIA
  • PUBLICATIONS
  • CASE-BASED ROUNDTABLE
  • PARTNERS
  • RESOURCES
  • SUBSCRIBE
  • BRAIN CANCER
  • BREAST CANCER
    • HER2 Breast Cancer
  • COMMUNITY ONCOLOGY PRACTICE
  • GENITOURINARY CANCERS
    • Bladder Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • GENOMIC TESTING
    • Liquid Biopsies
  • GI CANCERS
    • Pancreatic Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • GIST
    • HCC
  • GYNECOLOGIC CANCERS
    • Cervical Cancer
    • Endometrial Cancer
    • Ovarian Cancer
  • HEAD & NECK CANCERS
  • HEMATOLOGY
    • Bone Marrow & Stem Cell Transplant
  • IMMUNOTHERAPY
    • CAR T-Cell Therapy
  • LEUKEMIAS
    • AML
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • LUNG CANCER
    • MET-Targeted Therapy
    • Small Cell Lung Cancer
    • Biomarker-Driven Lung Cancer
    • EGFR+ Lung Cancer
  • LYMPHOMAS
    • DLBCL
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
  • MPNs
  • MULTIPLE MYELOMA
  • NTRK GENE FUSIONS
  • ONCOLOGY POLICY
  • SARCOMA
  • SKIN CANCERS
    • Melanoma
  • THYROID CANCERS
Spotlight -
Community Oncology Practice|
Oncology Policy|
Myeloma|
CLL|
Genomic Testing|
GU Cancers
Advertisement

Jorge A. Garcia, MD, FACP

Advertisement

Articles by Jorge A. Garcia, MD, FACP

Role of Multidisciplinary Management in mCRPC

ByJorge A. Garcia, MD, FACP
May 19th 2020

Importance of Bone Health Agents in mCRPC Management

ByJorge A. Garcia, MD, FACP
May 19th 2020

Combination of Radium-223 With Other Novel Agents in mCRPC

ByJorge A. Garcia, MD, FACP
May 19th 2020

Radium 223: Counseling Patients With mCRPC

ByJorge A. Garcia, MD, FACP
May 19th 2020

Management of mCRPC: Radium-223

ByJorge A. Garcia, MD, FACP
May 19th 2020

Approaching Therapy for mCRPC

ByJorge A. Garcia, MD, FACP
May 19th 2020

Therapeutic Options for mCRPC

ByJorge A. Garcia, MD, FACP
May 19th 2020

Standard of Care for mCRPC

ByJorge A. Garcia, MD, FACP
May 19th 2020

Case Overview: 69-Year-Old Man With Advanced CRPC

ByJorge A. Garcia, MD, FACP
May 19th 2020

A 69-Year-Old Man With Advanced Castrate-Resistant Prostate Cancer

ByJorge A. Garcia, MD, FACP
May 19th 2020

Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.

Advertisement

Latest Updated Articles

  • Management of mCRPC: Radium-223
    Management of mCRPC: Radium-223

    May 19th 2020

  • Radium 223: Counseling Patients With mCRPC
    Radium 223: Counseling Patients With mCRPC

    May 19th 2020

  • Case Overview: 69-Year-Old Man With Advanced CRPC
    Case Overview: 69-Year-Old Man With Advanced CRPC

    May 19th 2020

  • Approaching Therapy for mCRPC
    Approaching Therapy for mCRPC

    May 19th 2020

  • Standard of Care for mCRPC
    Standard of Care for mCRPC

    May 19th 2020

  • Combination of Radium-223 With Other Novel Agents in mCRPC
    Combination of Radium-223 With Other Novel Agents in mCRPC

    May 19th 2020



Advertisement
Advertisement

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

1

ASCO 2026 GU Cancer Highlights: Beyond the LBAs

2

FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer

3

Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma

4

ASCO 2026 GI Cancer Highlights: Beyond the LBAs

5

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC

  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • Editorial Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us